-
1“…The results demonstrated that the prototype ARCHITECT assay is more sensitive in detecting HBsAg in the presence of anti-HBs than current HBsAg assays. …”
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
2av Holzmayer, Vera, Taylor, Russell, Kuhns, Mary C., Gawel, Susan H., Ndembi, Nicaise, Mbanya, Dora, Kaptue, Lazare, Rodgers, Mary A., Cloherty, Gavin“…We evaluated the use of DBS whole blood samples in the modified Abbott ARCHITECT anti-HCV assay, comparing assay performance against the standard assay run using DBS and venous plasma samples. 144 HCV positive and 104 HCV negative matched venous plasma and whole blood specimens were selected from a retrospective study with convenience sampling in Cameroon. …”
Publicerad 2022
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
3av Rodgers, Mary A., Shah, Pir A., Anderson, Mark, Vallari, Ana S., Gersch, Jeffrey, Mbanya, Dora, Sauleda Oliveras, Silvia, Choudhry, Saad, Leary, Thomas P., Kuhns, Mary C., Dawson, George J., Cloherty, Gavin A., Lau, Daryl T.Y.“…To evaluate the clinical utility of HBsAg isoforms, we developed novel prototype assays on the ARCHITECT automated serology platform that specifically detects total-HBsAg (T-HBsAg), large (L-HBsAg), and middle (M-HBsAg) products of the S gene to determine the isoform composition of human specimens from acute and chronic HBV infection and during long-term nucleos(t)ide analog therapy. …”
Publicerad 2023
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
4Development and performance of prototype serologic and molecular tests for hepatitis delta infectionav Coller, Kelly E., Butler, Emily K., Luk, Ka-Cheung, Rodgers, Mary A., Cassidy, Michael, Gersch, Jeffrey, McNamara, Anne L., Kuhns, Mary C., Dawson, George J., Kaptue, Lazare, Bremer, Birgit, Wedemeyer, Heiner, Cloherty, Gavin A.“…Prototype molecular (RNA) and serologic (IgG) assays were developed for high-throughput testing on the Abbott m2000 and ARCHITECT systems, respectively. RNA detection was achieved through amplification of a ribozyme region target, with a limit of detection of 5 IU/ml. …”
Publicerad 2018
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
5av Bazinet, Michel, Pântea, Victor, Cebotarescu, Valentin, Cojuhari, Lilia, Jimbei, Pavlina, Anderson, Mark, Gersch, Jeff, Holzmayer, Vera, Elsner, Carina, Krawczyk, Adalbert, Kuhns, Mary C., Cloherty, Gavin, Dittmer, Ulf, Vaillant, Andrew“…Supplemental analysis included high‐sensitivity HBsAg (Abbott ARCHITECT HBsAg NEXT), HBV pregenomic RNA (pgRNA), HBsAg/hepatitis B surface antibody (anti‐HBs) immune complexes (HBsAg ICs), and hepatitis B core‐related antigen (HBcrAg). …”
Publicerad 2020
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
6av Kuhns, Mary C., Holzmayer, Vera, Anderson, Mark, McNamara, Anne L., Sauleda, Silvia, Mbanya, Dora, Duong, Pham T., Dung, Nguyen T. T., Cloherty, Gavin A.“…Methods: A total of 347 samples collected from the USA, South Africa, Spain, Cameroon, Vietnam, and Cote D’Ivoire representing NAT yield (HBsAg(−), antibody to HBV core antigen (anti-HBc)(−), HBV DNA(+), N = 131), OBI (HBsAg(−), anti-HBc(+), HBV DNA(+), N = 188), and HSLD (HBsAg(+), anti-HBc(+), HBV DNA(+), N = 28) were tested with ARCHITECT HBsAg NEXT (HBsAgNx) (sensitivity 0.005 IU/mL). …”
Publicerad 2021
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text -
7av Kuhns, Mary C., Holzmayer, Vera, McNamara, Anne L., Anderson, Mark, Cloherty, Gavin A.“…Testing included quantitative hepatitis B surface antigen (HBsAg), antibodies to HBV antigens, quantitative HBV e antigen (HBeAg), HBV DNA, quantitative HBV core-related antigen (HBcrAg), the highly sensitive ARCHITECT HBsAg NEXT (HBsAgNx) assay, and a quantitative research assay for HBV pregenomic RNA (pg RNA). …”
Publicerad 2021
Hämta fulltext
Hämta fulltext
Hämta fulltext
Online Artikel Text